Year None202420232022202120202019201820172016 Date Latest Press Release August 5, 2021 Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism August 3, 2021 Eiger BioPharmaceuticals to Participate in Upcoming August 2021 Investor Conferences July 22, 2021 Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2021 Financial Results and Business Update on Thursday, August 5 July 7, 2021 Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference July 6, 2021 Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients July 2, 2021 Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) June 29, 2021 Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib) June 28, 2021 Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session May 26, 2021 Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
